News & Updates
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Jupiter, FL – [August 19, 2025] – Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program. The fundi...
Read moreMyosin Therapeutics Awarded $3 Million NIH Grant to Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder
Jupiter, FL – Apr 28, 2025, 14:00 ET – Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, today announced that it has been awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), part of the National Institut...
Read moreMyosin Therapeutics Closes Second Seed Round to Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Hea...
Read moreMyosin Therapeutics Successfully Transitions to Second Phase of NCI’s Fast Track Funding to Advance MT-125
Jupiter, FL - [January 16, 2024] – After milestone review by the NIH’s National Cancer Institute (NCI), Myosin Therapeutics is excited to announce that it has successfully transitioned to the second phase of funding through the NCI Small Business Technology Transfer (STTR) Fast Track program. Myosin...
Read moreMyosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder
Jupiter, FL - [March 7th, 2023] – Myosin Therapeutics Inc., a biotechnology company leveraging its innovative platform technology to identify new molecular entities capable of selectively targeting nanomotor proteins, announced today that it supplemented its National Institutes of Health (NIH) fundi...
Read more